The clinical cohort 1 included 814 PC patient, of whom 136 had BoM and 678 had no BoM; 121 LC patients, of whom 50 had BoM and 71 had no BoM; 66 BC patients, of whom 25 had BoM and 41 had no BoM (Supplementary Table S2). Here, GRHL2 is linked to breast cancer.